OBJECTIVE: Methamphetamine is one of the most commonly used illicit drugs during pregnancy, highlighting the importance of understanding the risks associated with its use and adverse pregnancy outcomes. We sought to determine the association between methamphetamine use and pregnancy outcomes in a large cohort of US women. STUDY DESIGN: This was a retrospective cohort study of pregnancies in California from 2007 to 2011 using the California birth registry. Subjects were stratified into two groups: methamphetamines use during pregnancy versus no methamphetamine use. We assessed maternal demographics and characteristics in addition to pregnancy outcomes. Differences were analyzed by Pearson's chi-square, t-test, and logisticregression, with a¼0.05.
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RESULTS:
Of 2,393,939 non-anomalous singleton pregnancies 23 to 42 weeks' gestation, 9,423 (0.39%) of women used methamphetamines during pregnancy. Methamphetamine users were more likely to be diagnosed with gestational hypertension or preeclampsia (10.6% vs 5.7%, p<0.001) and had an increased probability of severe maternal morbidity (4.2% vs 1.1%, p<0.001) ( Table 1) . Preterm delivery <37 weeks (29.4% vs 10.6% p<0.001) and neonatal hypoglycemia (1.9% vs 0.8%, p<0.001) were also more common among methamphetamine users. When adjusting for maternal characteristics and other substance use (tobacco, cannabis, and opioids), methamphetamine use was associated with multiple adverse maternal and neonatal outcomes (Figure 1) . CONCLUSION: Among a large cohort of pregnant women, methamphetamine use was associated with an increased odds of severe maternal morbidity, in addition to multiple other adverse maternal and neonatal outcomes. This reinforces the importance of identifying methamphetamine use during pregnancy to mitigate these adverse outcomes.
313 Medication-Assisted Treatment (MAT) in pregnancy: methadone and buprenorphine Cara Staszewski, Kimberly Herrera, Malini D. Persad, Victoria Ly, Diana Garretto, Jay Davis, David J. Garry Stony Brook University Hospital, Stony Brook, NY OBJECTIVE: To compare pregnancy outcomes in Medication-Assisted Treatment (MAT) with methadone or buprenorphine. STUDY DESIGN: A retrospective cohort of women receiving MAT with either methadone or buprenorphine were identified from delivery and newborn records at our tertiary care hospital over a 10-year period. Women were excluded with delivery less than 24 weeks, a multiple gestation, or a known anomalous fetus. Maternal demographics, medications, GA and mode of delivery, birthweight, newborn length of stay, and neonatal abstinence syndrome were extracted from the medical record. The study was IRB approved and OBJECTIVE: To explore the effects of gestational OMT on placental development STUDY DESIGN: This is a retrospective cohort study of pregnant patients on OMT (buprenorphine or methadone) between January 2007 and December 2017. ICD codes were used to identify OMT patients. The control group consisted of random non-drug users matched for GA. Patients were excluded if they had gestational diabetes, multiple gestations, positive meconium toxicology results for substances other than methadone or buprenorphine and those without microscopic placental evaluation. Placental weight and histologic evaluation were obtained and compared among the groups. Data analysis was performed using one-way ANOVA with pvalue <0.05 significant. RESULTS: 454 cases were reviewed; of which 109 met the inclusion criteria (66 patients were on methadone, 43 were on buprenorphine, and 40 were controls). Gestational age at birth and neonatal birth weight were significantly lower in the methadone group compared to the buprenorphine and control groups . The placenta to neonatal birth weight ratio was significantly higher in the methadone and buprenorphine groups compared to controls (p<0.01). There was no statistically significant difference between methadone and buprenorphine groups (mean AE standard deviation; methadone: 0.19 AE 0.03; buprenorphine: 0.18 AE 0.04; control: 0.15 AE 0.03).The rate ratio of placental dysmaturity (Figure 1 ) was significantly higher in the methadone and buprenorphine groups compared to control (rate ratio 3.8 and 3.7) CONCLUSION: Gestational OMT is associated with placentomegaly and placental dysmaturity compared to non-drug users. These findings are correlated with reduced surface area for oxygen diffusion, which may affect neonatal well-being. Further analysis is underway to evaluate the effects of placental dysmaturity on neonatal outcomes. OBJECTIVE: Neonates exposed to opioids in utero present a growing public health crisis in the US as the incidence of neonatal opioid withdrawal (NOW) has nearly tripled in the last two decades. Treatment of NOW can vary among hospitals thereby making it difficult to identify the most effective approach. Non-pharmacological management, such as parental presence, rooming-in, and breastfeeding, have been shown to decrease the severity of withdrawal. Studies suggest that infants with NOW who require pharmacologic treatment have lower cognitive scores. The objective of this study was to determine the optimal management strategy of NOW and its effects on neurodevelopmental outcomes.
